PIK3CA and breast carcinoma: As exosome-targeted nanomedicine presents promising opportunities for cancer therapy, developing nanodrugs that target MDSC-derived exosomes may offer a breakthrough in treating PIK3CA-mutant breast cancer [[27], [28], [29]].